作者:Miroslav Novák、Hana Hošnová、Libor Dostál、Britta Glowacki、Klaus Jurkschat、Antonín Lyčka、Zdenka Ruzickova、Roman Jambor
DOI:10.1002/chem.201604892
日期:2017.3.2
Treatment of the neutral pyridine‐based ligands L1–L3, bearing either one or two RN=CH imine moieties where L1 and L2 are N,N‐chelating ligands 2‐(RN=CH)C5H4N (R=Ph (L1) or R=2,4,6‐Ph3C6H2 (L2)) and L3 is the N,N,N‐chelating ligand 2,6‐(RN=CH)2C5H3N (R=2,6‐iPr2C6H3)}, with HSiCl3 yielded N→Si‐coordinated silicon(IV) amides 2‐Cl3SiN(R)CH2}C5H4N (1, R=Ph; 2, R=2,4,6‐Ph3C6H2) and 2‐Cl3SiN(R)CH2}‐6‐(RN=CH)C5H4N
处理带有一个或两个RN = CH亚胺部分的中性吡啶基中性配体L 1 - L 3 其中L 1和L 2是N,N-螯合配体2-(RN = CH)C 5 H 4 N (R = Ph(L 1)或R = 2,4,6-Ph 3 C 6 H 2(L 2))并且L 3是N,N,N-螯合配体2,6-(RN = CH)2 C 5 H 3 N(R = 2,6‐ i Pr 2 C 6 H 3)},用HSiCl 3生成N→Si配位的硅(IV)酰胺2- Cl 3 SiN(R)CH 2 } C 5 H 4 N(1,R = Ph; 2,R = 2,4,6 -Ph 3 C 6 H 2)和2- Cl 3 SiN(R)CH 2 } -6-(RN = CH)C 5 H 4 N(3,R = 2,6 - i Pr 2 C 6 H 3)。有机硅酰胺1 - 3是拟议的N,N螯合的氯硅烷L 1 →SiHCl 3(1 a),L 2 →SiHCl